Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Global R&D, CSO | June 16, 2014 | June 18, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 16, 2014 · Filed June 18, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,017 |
Reported balance
After 2014-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-06-16 · Exercise / conversion · Acquired 7,500 · Balance 151,017 |
| Common StockSEC Table I · non-derivative | Direct | 146,614 |
Reported balance
After 2014-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2014-06-16 · Sale · Disposed 4,403 · Balance 146,614 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 145,114 |
Reported balance
After 2014-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2014-06-16 · Sale · Disposed 1,500 · Balance 145,114 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86). |
| Common StockSEC Table I · non-derivative | Direct | 143,517 |
Reported balance
After 2014-06-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2014-06-16 · Sale · Disposed 1,000 · Balance 143,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99). |
| Common StockSEC Table I · non-derivative | Direct | 144,517 |
Reported balance
After 2014-06-16 transaction · row 4
1 source rowRow 4 · 2014-06-16 · Sale · Disposed 597 · Balance 144,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2018-07-23 | Direct | 15,500 |
Reported balance
After 2014-06-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-06-16 · Exercise / conversion · Disposed 7,500 · Balance 15,500 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,770 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,770 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 5,568 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,568 |
| Common StockSEC Table I · non-derivative | IndirectCommon stock held in trust | 15,233 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 15,233 F7: Common stock held in grantor retained annuity trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96).
F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).
F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).
F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).
F7: Common stock held in grantor retained annuity trust.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2008 Filed Dec 16, 2008 18:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-08-000096 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2008 Filed Nov 19, 2008 17:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-08-000084 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 17, 2008 Filed Nov 19, 2008 17:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $27.14 | $65,136.00 |
DisclosureSEC source: 0000875320-08-000084 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $27.14 (range $26.85 to $27.49). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2008 Filed Nov 19, 2008 17:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-08-000084 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 19:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-08-000078 · edgar.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 19:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 480 | $27.74 | $13,315.20 |
DisclosureSEC source: 0000875320-08-000078 · edgar.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F4 · price: Open market sales reported on this line occurred at a weighted average price of $27.74 (range $27.61 to $27.87). F5 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 19:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $26.84 | $32,208.00 |
DisclosureSEC source: 0000875320-08-000078 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,870 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $26.84 (range $26.44 to $27.36). F5 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 19:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 720 | $25.73 | $18,525.60 |
DisclosureSEC source: 0000875320-08-000078 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,070 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $25.73 (range $25.35 to $26.18). F5 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 19:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-08-000078 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2008 Filed Sep 19, 2008 15:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-08-000074 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 17, 2008 Filed Sep 19, 2008 15:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $27.94 | $67,056.00 |
DisclosureSEC source: 0000875320-08-000074 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $27.94 (range $27.46 to $28.40). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2008 Filed Sep 19, 2008 15:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-08-000074 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2008 Filed Jul 25, 2008 15:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 36,250 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0000875320-08-000057 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2018-07-23 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/24/2008. Read SEC document |
| July 15, 2008 Filed Jul 17, 2008 16:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-08-000050 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 15, 2008 Filed Jul 17, 2008 16:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $32.21 | $38,652.00 |
DisclosureSEC source: 0000875320-08-000050 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $32.21 (range $32.08 to $32.33). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2008 Filed Jul 17, 2008 16:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $32.59 | $39,108.00 |
DisclosureSEC source: 0000875320-08-000050 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,590 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.59 (range $32.38 to $33.10). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2008 Filed Jul 17, 2008 16:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-08-000050 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.37 | $5,474.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 11 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.19 | $5,438.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 10 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,590 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.16 | $2,716.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 9 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,790 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.15 | $2,715.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 8 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,890 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.11 | $5,422.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 7 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,990 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.09 | $2,709.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,190 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 102 | $27.05 | $2,759.10 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,290 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 105 | $27.04 | $2,839.20 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,392 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 34 | $27.03 | $919.02 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,497 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.01 | $8,103.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,531 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.00 | $2,700.00 |
DisclosureSEC source: 0000875320-08-000023 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,831 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 72,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-08-000009 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2018-02-06 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0000875320-08-000009 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,931 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| July 12, 2007 Filed Jul 16, 2007 18:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,250 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000079 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2017-07-11 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/12/2007. Read SEC document |
| May 07, 2007 Filed May 8, 2007 19:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,401 | $30.59 | $348,756.59 |
DisclosureSEC source: 0000875320-07-000047 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,430 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| January 24, 2007 Filed Jan 26, 2007 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 54,375 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0000875320-07-000015 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2017-01-23 F3 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 01/24/2007. Read SEC document |
| January 24, 2007 Filed Jan 26, 2007 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,000 | $0.01 | $200.00 |
DisclosureSEC source: 0000875320-07-000015 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,831 F2 · shares: Stock grant made under 2006 Stock and Option Plan, vesting as to 5,000 shares on May 6, 2008, and as to 15,000 shares on May 6, 2010. Read SEC document |
| January 24, 2007 Filed Jan 26, 2007 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-07-000015 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,831 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 1/24/2011, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 19, 2006 Filed Dec 20, 2006 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 165 | $38.00 | $6,270.00 |
DisclosureSEC source: 0000875320-06-000123 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,747 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| November 20, 2006 Filed Nov 21, 2006 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 32,314 | $45.00 | $1,454,130.00 |
DisclosureSEC source: 0000875320-06-000099 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,912 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| November 16, 2006 Filed Nov 17, 2006 19:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerStock Option · Derivative | 17,686 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000875320-06-000098 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,864 Underlying: Common Stock · 17,686 shares Expires 2013-07-14 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 20 equal quarterly installments from 07/15/2003. Read SEC document |
| November 16, 2006 Filed Nov 17, 2006 19:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,686 | $45.00 | $795,870.00 |
DisclosureSEC source: 0000875320-06-000098 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,226 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| November 16, 2006 Filed Nov 17, 2006 19:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,686 | $16.32 | $288,635.52 |
DisclosureSEC source: 0000875320-06-000098 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2006 Filed Jul 24, 2006 17:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,250 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0000875320-06-000066 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO&EVP Drug Innov&Realization 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,550 Underlying: Common Stock · 36,250 shares Expires 2016-07-19 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2006. Read SEC document |
| March 20, 2006 Filed Mar 21, 2006 14:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 305 | $40.00 | $12,200.00 |
DisclosureSEC source: 0000875320-06-000027 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & EVP Drug Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,226 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 73,500 | $0.00 Strike: $35.64 | $0.00 |
DisclosureSEC source: 0000875320-06-000010 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Disc., Innov & Realiz 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,300 Underlying: Common Stock · 73,500 shares Expires 2016-02-01 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/02/2006. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,200 | $0.01 | $122.00 |
DisclosureSEC source: 0000875320-06-000010 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Disc., Innov & Realiz 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,531 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 02/02/2010, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| January 06, 2006 Filed Jan 9, 2006 18:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,213 | $30.78 | $37,336.14 |
DisclosureSEC source: 0000875320-06-000001 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,331 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| December 21, 2005 Filed Dec 21, 2005 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,496 | $27.84 | $41,648.64 |
DisclosureSEC source: 0000875320-05-000076 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,554 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 20, 2005 Filed Jul 22, 2005 19:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-05-000047 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,800 Underlying: Common Stock · 18,000 shares Expires 2015-07-19 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,000 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-05-000012 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,800 Underlying: Common Stock · 36,000 shares Expires 2015-02-02 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,200 | $0.01 | $72.00 |
DisclosureSEC source: 0000875320-05-000012 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,040 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 02/03/2009, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| October 07, 2004 Filed Oct 12, 2004 18:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-04-000111 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,800 Underlying: Common Stock · 18,000 shares Expires 2014-10-06 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.